Department of Diabetes and Hormone Diseases (DoH)
Aarhus N, 8200, Denmark
NCT Number: NCT05762822
Polycystic ovarian syndrome (PCOS) is characterized by elevated androgens such as testosterone. Clinical studies suggest that ketogenic diets lower the levels of androgens. The ketone 3-hydroxybutyrate (3-OHB) may play an important role in these effects and the main purpose of this study is to investigate whether a 3-OHB supplement acutely improves the hormonal and metabolic status in women with PCOS.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Not applicable
Aarhus N, 8200, Denmark
Polycystic ovary syndrome (PCOS) affects 5-18% of women and is characterized by the presence of two of three of the Rotterdam criteria: Hyperandrogenism (clinical or biochemical), irregular menstrual cycles, and polycystic ovary morphology, after exclusion of other conditions that mimic PCOS. PCOS is associated with elevated levels of luteinizing hormone (LH) and unaltered levels of the follicle stimulating hormone (FSH), which leads to the characteristic hyperandrogenism (high levels of testosterone), oligo- or anovulation, and a large number of premature follicles in the ovarian. Insulin resistance causes hyperinsulinemia that decreases sex hormone binding globulin (SHBG) levels and stimulates androgen production (e.g., elevated concentrations of testosterone). Ketogenic diets are characterized by a diet low in carbohydrates, and has shown beneficial effects on weight and hormonal status in women with PCOS. Whether these improvements are mediated by ketones (e.g., 3-hydroxybutyrate, 3-OHB) or other effects related to this diet is unknown. The main purpose of this study is to investigate whether a 3-OHB supplement acutely improves the hormonal and metabolic status in women with PCOS.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
60 ml (30 g) of 3-OHB
Other names: ketone supplement
60 ml water (added bitter taste)
Time frame: 10 hours after first intervention
Paired t-test
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
Time frame: 10 hours after first intervention
University of Aarhus
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07513480
PCOS
Dhaka, Shahbag, Bangladesh
View Trial DetailsNCT06530498
Adnexal Diseases, Alopecia
Krakow, Poland
View Trial DetailsNCT03919929
Adolescent Obesity, Body Weight
Aurora, Colorado, United States
View Trial DetailsNCT05971849
Adnexal Diseases, Cysts
Boston, Massachusetts, United States
View Trial Details